PAS funded by this sponsor. EU PAS ID Status RMP requirementTitle Protocol uploaded Results uploaded 2353 Finalised Not included in RMP The risk of acute liver injury associated with the use of antibiotics. A methodological comparison across epidemiological data sources Yes No 2356 Finalised Not included in RMP Use of antiepileptics and risk of suicidality. An exploratory study using the UK General Practice Research Database (GPRD) and data from the Danish... Yes Yes 2382 Finalised Not included in RMP Use of antidepressants and risk of hip/femur fracture. A methodological comparison across data sources and epidemiological design Yes No 2385 Ongoing Unspecified Use of benzodiazepines and risk of hip/femur fracture. A methodological comparison across data sources and epidemiological design. Yes No 2388 Ongoing Unspecified Calcium channel blocker treatments and cancer risk. A methodological protocol to compare the results between databases, across designs: Evaluation of... Yes No 2561 Ongoing Unspecified Use of inhaled long acting beta2 adrenoceptor agonists and the risk for Acute Myocardial Infarction (AMI). A methodological comparison across data... Yes No 3180 Finalised Not included in RMP Prospective Observational Cohort Study to Describe the Use of Vectibix® in Combination With Chemotherapy in Routine Clinical Practice for Patients... Yes Yes 5345 Finalised Unspecified Survey of Oncology Practitioners Prescribing XGEVA® in Europe to Evaluate Their Knowledge of XGEVA® Summary of Product Characteristics Pertaining to... Yes Yes 5605 Finalised Not included in RMP Osteonecrosis of the Jaw (ONJ) Case Registry Yes Yes 5641 Finalised Unspecified Effect of Cinacalcet Discontinuation on Biochemical Control for Medicare Beneficiaries with Part D Coverage Treated within a Large US Dialysis... Yes Yes 5644 Finalised Unspecified Risk factors For Bone Pain among Neulasta® Users (20120320) Yes Yes 5647 Finalised Not included in RMP A Prospective Cohort Study to Describe Use and Safety of Cinacalcet in Pediatric Patients Receiving Dialysis in the NAPRTCS Registry (20120116) Yes Yes 5681 Finalised EU RMP category 1 Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Use in Europe (20101120) Yes Yes 5687 Finalised EU RMP category 3 Estimation of Off-Label Use of XGEVA® (denosumab) Using Population-Based Databases in Denmark (20101335) Yes Yes 6210 Finalised Unspecified Characterizing the Management of Hypocalcemia Among Patients on Hemodialysis Receiving Cinacalcet Treated Within a Large US Dialysis Provider... Yes Yes 6658 Finalised EU RMP category 3 A cross-sectional study of patients with immune thrombocytopenic purpura and caregivers to estimate the proportion who administer romiplostim... No Yes 8054 Finalised Non-EU RMP-only Burden of serious infection in patients with rheumatoid arthritis treated with Prolia ovserved in a clinical setting (20140127) Yes Yes 11186 Finalised EU RMP category 3 Primary Immune Thrombocytopenia Treated with Romiplostim (20140451) No Yes 11662 Finalised Not included in RMP Occurrence of serious infection among patients with rheumatoid arthritis or psoriatic arthritis concurrently exposed to an immunosuppressive biologic... Yes Yes 11891 Finalised EU RMP category 3 A longitudinal study of 4 cohorts of patients with psoriasis and psoriatic arthritis: one treated with Otezla (apremilast), one with an injectable... No Yes 13328 Finalised Not included in RMP Observational Serial Chart Review of Repatha® Use in European Subjects with Hyperlipidaemia (20130296) Yes Yes 13518 Finalised Not included in RMP Risk factors for cardiac events in carfilzomib-treated patients in the Marketscan database (20160186) Yes Yes 13676 Ongoing Non-EU RMP-only Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan (20140409) (Evolocumab Long term PMS Japan) Yes No 13794 Finalised Not included in RMP An observational study of patients with Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia in the US (20150253) Yes Yes 15128 Ongoing EU RMP category 3 A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® (Talimogene Laherparepvec) in Clinical Practice to Characterize... No No 15153 Finalised EU RMP category 3 A Multinational Observational Study to Evaluate the Safety of Repatha® in Pregnancy (20150162) Yes Yes 16291 Finalised Not included in RMP Getting to an imprOved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia management (GOULD): a Registry of High Cardiovascular... Yes Yes 16302 Finalised EU RMP category 3 A retrospective analysis of pre-existing and acquired major adverse cardiovascular events (MACE) in a real world cohort of multiple myeloma (MM)... Yes Yes 16626 Finalised EU RMP category 3 Survey of Physicians, Pharmacists, and Nurses Involved in the Prescribing, Preparation and Administration of Blincyto in Europe to Evaluate the... Yes Yes 17198 Finalised Not included in RMP Prolia® Postmarketing Active Safety Surveillance Program for Soliciting Adverse Events of Special Interest in the United States (PASP-EMR Program) Yes Yes 17390 Finalised Not included in RMP Characterizing the management of hypocalcemia among European hemodialysis patients receiving cinacalcet (20150330) Yes Yes 17410 Finalised Not included in RMP Clinical Characteristics of The First IMLYGIC™ Patients With Unresectable Stage IIIB-IVM1a Melanoma Treated in Routine Clinical Practice, in Selected... Yes Yes 17829 Finalised EU RMP category 3 A cross-sectional survey of patients and caregivers receiving Blincyto in routine clinical practice in Europe to evaluate the effectiveness of... Yes Yes 17848 Ongoing EU RMP category 1 An observational study of blinatumomab safety and effectiveness, utilisation, and treatment practices (20150136) No No 17915 Finalised Non-EU RMP-only Postmarketing Surveillance Study of Prolia (Denosumab) in South Korea Yes Yes 18060 Finalised Not included in RMP A Survey of Medical Oncologist’s Opinions and Perceptions Regarding the Management of Dermatologic Toxicities among mCRC Patients Treated with... No Yes 18108 Ongoing Non-EU RMP-only Postmarketing Surveillance Study for Kyprolis® (carfilzomib) in Korea (20160117) Yes Yes 18114 Finalised Non-EU RMP-only Postmarketing Surveillance Study of XGEVA (Denosumab) in South Korea (20160198) Yes Yes 18402 Finalised Not included in RMP Persistence and compliance to anti-osteoporosis medications in the United Kingdom using the Clinical Practice Research Datalink (CPRD) (20160192) Yes Yes 18916 Finalised Non-EU RMP-only Prospective Observational Study to Describe Characteristics and Management of Patients With Osteoporosis Treated With Prolia® in Routine Clinical... Yes Yes 18923 Finalised Not included in RMP A Multi-country Prospective Observational Study to Describe Calcimimetic Use in Haemodialysis Patients Yes Yes 19053 Ongoing Not included in RMP An observational study of Cardiovascular complications of Carfilzomib treatment in clinical practice (Cardiovascular complications of carfilzomib) Yes No 19116 Finalised Non-EU RMP-only Healthcare Providers’ Awareness of the risks and safe use conditions associated with BLINCYTO®: A REMS Assessment Survey (20170108) Yes Yes 19126 Finalised Not included in RMP Incidence of Hematologic and Non-Hematologic Malignancies, Thrombotic Events, and Autoimmune Disorders in Unrelated Normal Donors Undergoing Bone... Yes Yes 19156 Finalised Not included in RMP Prolia® persistence in post-menopausal women with osteoporosis, over 70 years, at increased risk of fracture, treated in routine clinical practice in... Yes Yes 19680 Finalised Non-EU RMP-only A post-marketing surveillance study for Repatha Inj. (evolocumab) in Korea text (20160156) Yes Yes 19718 Finalised EU RMP category 3 Association Between Granulocyte Colony Stimulating Factor (G-CSF) use and Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Among Elderly... Yes Yes 19961 Finalised Not included in RMP Expanded access of Blincyto® in patients with acute lymphoblastic leukaemia: a retrospective observational study (Neuf Study) (20160441) Yes Yes 20043 Finalised Not included in RMP RETrospective Observational Study of Evolocumab Use in Spanish Endocrinology Units (RETOSS-Endo) (20160140) Yes Yes 20687 Finalised Not included in RMP Longitudinal study on the epidemiology and management of auto-immune thrombocytopenia (AITP) in Algeria Yes Yes 21542 Ongoing Not included in RMP Prospective Observational Non-interventional Study to Describe Characteristics and Management of Patients With Giant Cell Tumor of Bone Treated With... Yes No 21914 Finalised Not included in RMP An Observational Study to Evaluate the Potential Association Between Cinacalcet and Gastrointestinal Bleeding (20170171) Yes Yes 22075 Finalised Not included in RMP EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care DA VINCI Yes Yes 23186 Finalised EU RMP category 3 An Observational Study to Evaluate the Potential Association Between ParsabivTM and Gastrointestinal Bleeding (20170561) No Yes 23268 Finalised Not included in RMP Cinacalcet Use and the Risk of Gastrointestinal (GI) Bleeding Among Hemodialysis Patients with Secondary Hyperparathyroidism (SHPT) in DOPPS Yes Yes 24079 Ongoing Not included in RMP Use of Erythropoiesis Stimulating Agents (ESA) in Patients With Non-myeloid Malignancies Receiving Myelosuppressive Chemotherapy 2014 – 2021 No No 24541 Finalised Not included in RMP Prospective Observational Study to Describe Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France... Yes Yes 24626 Finalised Not included in RMP A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) among Subjects with Non-myeloid Malignancies at High Risk for... Yes Yes 24775 Finalised Not included in RMP Integrated Retrospective Analysis of Metastatic-related and Non metastatic-related Fractures in Studies 20050136, 20050244, and 20050103 Yes Yes 24954 Ongoing EU RMP category 3 An Observational Registry Study To Evaluate The Use And Safety Of Cinacalcet Among Paediatric Patients With Secondary Hyperparathyroidism (20180204) No No 25381 Finalised EU RMP category 3 Incidence of new Primary Malignancies Among Patients With Bone Metastases From Breast, Prostate, or Lung Cancer Treated With XGEVA or Intravenous... Yes Yes 25858 Finalised Not included in RMP Assessment of the ‘Managing Advanced Cancer Pain Together’ (MACPT) tool to facilitate communication on total cancer pain between advanced cancer... Yes Yes 26165 Ongoing Not included in RMP Multicenter Assessment of Treatment Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia (20180232)... No No 26372 Finalised Not included in RMP The use, safety, and effectiveness of Prolia in clinical practice among Chinese women with post-menopausal osteoporosis ─ Taiwan and Hong Kong... Yes Yes 26499 Finalised Not included in RMP POWER: Real World Data of 1st line panitumumab treatment in combination with chemotherapy in non resectable wild type (WT) RAS metastatic colorectal... Yes Yes 26530 Finalised Non-EU RMP-only All Case Post Marketing Drug Use Result Survey for Blinatumomab in Japan (20170655) (Blinatumomab All Case PMS Japan) Yes Yes 26983 Finalised Non-EU RMP-only Prospective observational study to describe routine use of XGEVAâ for prevention of skeletal related events (SREs) in subjects with bone metastases... Yes Yes 27121 Ongoing Not included in RMP A retrospective analysis of overall response and survival to 1st+ salvage therapy in T-cell and 2nd+ salvage therapy in B-cell pediatric acute... No No 27161 Finalised Not included in RMP Users of pegfilgrastim less than or equal to 13 years of age (20180440) (Users of pegfilgrastim =< 13 years) Yes Yes 27382 Finalised EU RMP category 3 Long-term Follow-up of Adult Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia Relapsed Refractory Patients Enrolled in Study 00103311... Yes Yes 27559 Ongoing EU RMP category 3 Denosumab Global Safety Assessment in Multiple Observational Databases (20090522) No No 27845 Finalised Not included in RMP Calcimimetics Adherence and Preference Study in the Management of Secondary Hyperparathyroidism in Europe Yes Yes 28762 Finalised EU RMP category 3 An Observational Study to Assess the Effectiveness of the Neulasta® Patient Alert Card and to Measure Medication Errors Related to the Use of the... Yes Yes 29415 Ongoing Not included in RMP Observational Patient Evidence for Regulatory Approval and uNderstanding Disease (OPERAND) No No 29685 Ongoing Non-EU RMP-only Long Term Post Marketing Drug Use Result Survey for Blinatumomab in Japan (20180238) (Blinatumomab Long Term PMS Japan) No No 30072 Finalised Not included in RMP Characterizing Repatha use among adult pregnant women, adult women of childbearing age and within the adult general population (NA) Yes Yes 30108 Finalised Not included in RMP GARDENIA: A Multi-country Observational Serial Chart Review Study of KANJINTI use in Europe Yes Yes 30334 Finalised Not included in RMP A Survey of Experiences and Opinions Regarding Skin Toxicities Associated with Vectibix Among mCRC Patients Yes Yes 30346 Ongoing Non-EU RMP-only Postmarketing Surveillance Study of EVENITY (Romosozumab) in South Korea (20170753) No No 30491 Planned Not included in RMP A Prospective Observational Study on Safety and Effectiveness of Denosumab Treatment in Chinese Patients with Giant Cell Tumor of Bone (20180118) No No 30506 Finalised Not included in RMP Osteoporosis outcomes and treatment patterns in France (20190017) No No 30534 Finalised Not included in RMP Real-world Evidence of the Use of Carfilzomib Among Multiple Myeloma Patients in Europe Who Have Received at Least One Prior Therapy (Use of... Yes Yes 30748 Finalised EU RMP category 3 An Observational Study to Estimate Incidence Rates of Heart Failure Among US Racial and Ethnic Minority Patients With Multiple Myeloma Treated or Not... Yes Yes 31161 Finalised Not included in RMP Utilization of Romiplostim in Myelodysplastic Syndromes (MDS) within the Medicare Population: A Study Based on Data from the Surveillance,... No Yes 31188 Finalised EU RMP category 3 A Cross-sectional Survey to Evaluate Physician Knowledge of Safety Messages Included in the Physician Education Booklet (PEB) for IMLYGIC® Yes Yes 31213 Finalised EU RMP category 3 A Cross-sectional Survey to Evaluate Patient Knowledge of Safety Messages Included in the Patient Safety Brochure and Patient Alert Card for IMLYGIC® Yes Yes 31796 Ongoing EU RMP category 3 A Prospective Observational Study to Evaluate Long-term Safety of AMGEVITA in Patients With Rheumatoid Arthritis (20160264) Yes No 31967 Finalised Not included in RMP Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving Q2W chemotherapy regimen: A systematic review of efficacy,... Yes Yes 32133 Finalised EU RMP category 3 Incidence of Cardiovascular and Cerebrovascular Events Among Postmenopausal Women and Men With Osteoporosis Who Initiated Treatment With Denosumab or... Yes Yes 32139 Finalised Not included in RMP Targeted Literature Review to Describe Safety Outcomes in Immune Thrombocytopenia Patients Treated With Thrombopoietin-Receptor Agonists Yes Yes 32183 Finalised Not included in RMP Romiplostim effectiveness stratified on duration of immune thrombocytopenia at initiation Yes Yes 32437 Finalised EU RMP category 3 A Non-interventional Pharmacovigilance Study of Osteonecrosis of the Jaw and Infection Leading to Hospitalization Among Patients With Cancer Treated... Yes Yes 32995 Ongoing Not included in RMP The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (20180059) (cvMOBIUS) Yes No 33657 Finalised Not included in RMP Use of Bone Marrow Biopsies in Patients With Chronic Immune Thrombocytopenia: Predictors For, And Prognosis After – a Nordic Population-based Cohort... Yes Yes 33745 Ongoing EU RMP category 3 Overall survival and incidence of adverse events in B-cell acute lymphoblastic leukemia (ALL) patients after allogeneic stem cell transplant:... Yes No 33862 Ongoing EU RMP category 1 Evaluation of Long-term Safety in Paediatric Patients With B-precursor Acute Lymphoblastic Leukemia (ALL) who Have Been Treated With Either... No No 34153 Finalised Non-EU RMP-only Users of pegfilgrastim less than or equal to 13 years of age (20200114) Yes Yes 34220 Finalised Not included in RMP Risk factors and incidence of inpatient constipation and inpatient constipation with serious complications among migraine patients treated with... Yes Yes 34590 Finalised Not included in RMP Canadian Retrospective Observational Study of MVASI in metastatic Colorectal Cancer (20180360) Yes Yes 34701 Finalised EU RMP category 3 Nordic Country Patient Registry for Romiplostim (NCPRR): Population-Based Prospective Annual Assessment of Safety of Romiplostim Treatment in Adult... Yes Yes 34832 Finalised Not included in RMP Estimating Event Rates Using the Medication Cohort Module: Hypertension and Negative Control Outcomes in New Users of Onabotulinumtoxin A and... Yes Yes 35042 Finalised Not included in RMP Topological Analysis of the baseline characteristics of relapsed and/or refractory multiple myeloma (R/R MM) patients treated with carfilzomib in... Yes No 36072 Ongoing Non-EU RMP-only OTEZLA® tablets General use-results survey (BCT) (20200279) No No 36417 Ongoing Not included in RMP Apremilast Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project Yes No 36684 Finalised Non-EU RMP-only OTEZLA® Tablets Drug Use-Results Survey (CC-10004-PSOR-018) No Yes 37160 Ongoing Non-EU RMP-only Clinical Characteristics, Including History of MI and Stroke, Among US Post-menopausal Women Initiating Treatment With Romosozumab and Other... No No 37499 Ongoing Not included in RMP Observational Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Erenumab-aooe During Pregnancy (20180172) No No 37529 Finalised Not included in RMP Global burden of hip fractures – trends in incidence, post-fracture treatment, and mortality; a multicountry, observational study (20190532) Yes Yes 37579 Ongoing Not included in RMP A Real-world, Prospective, Observational Study of Prolia® (20180401) No No 37799 Ongoing Not included in RMP GENESIS: AIMOVIG® Pregnancy Exposure Registry (20180125) No No 37838 Finalised Not included in RMP Comprehensive Analysis of Clinical Parameters That May Inform the Choice of Dose Regimen for Carfilzomib 20/27mg/m2 or 20/56mg/m2 With and Without... Yes Yes 37877 Finalised Not included in RMP Inpatient Constipation Among Migraine Patients Treated With Preventive Medications: A Retrospective Cohort Study in a United States Electronic Health... Yes Yes 38357 Finalised Not included in RMP RAStik: A Retrospective Cohort Analysis of Survival and Treatment Outcomes of Docetaxel in KRAS G12C Mutated Locally Advanced or Metastatic NSCLC... Yes Yes 38906 Finalised Not included in RMP Granulocyte Colony-Stimulating Factor (“G-CSF”): Patient profiles, Scheduling Patterns and Clinical Outcomes No Yes 39611 Finalised Not included in RMP The use and safety of XGEVA or Zoledronic acid in clinical practice among Chinese patients with bone metastases from breast, lung, or prostate cancer... Yes Yes 40607 Finalised Not included in RMP Patient characteristics and treatment of non-small cell lung cancer (NSCLC) patients – a Danish nationwide registry study (20200328) Yes Yes 40706 Ongoing Not included in RMP A Retrospective Cohort Study to Characterize Patient Characteristics and Treatment Outcomes Among Patients With Locally Advanced or Metastatic... No No 41626 Finalised Non-EU RMP-only Healthcare Providers’ Awareness of the Risks and Safety Associated With BLINCYTO® use: A 2021 REMS Assessment Survey (20210065) Yes Yes 41675 Finalised Not included in RMP Clinical Systematic Literature Review (SLR) of Ph(-) B-ALL in High-risk First Relapse Paediatric Patients Yes Yes 42393 Ongoing EU RMP category 3 An Observational Case Series to Describe Women Exposed to Repatha During Pregnancy and Infant Outcomes During the First Year of Life (20200408) No No 43115 Finalised EU RMP category 2 A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or... No Yes 44300 Finalised Not included in RMP ProSpective MultIcenter ObservationaL Study on the Quality of Life of mCRC RAS Wild-type Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st... Yes Yes 44961 Finalised Not included in RMP Hearing loss and risk of major osteoporotic fracture: a population-based cohort study in the United Kingdom (20200418) No Yes 45083 Finalised Not included in RMP The Safety and Clinical Effectiveness of Denosumab Among Chinese Men With Osteoporosis – a Real World Study in Taiwan (20210040) Yes Yes 45236 Planned Non-EU RMP-only Specific Drug Use-results Surveillance (Long-term) for Erenumab in Migraine Patients in Japan (20210048) No No 45799 Finalised Not included in RMP Risk of Hypertension, Acute Myocardial Infarction, and Stroke in Migraine Patients Treated With Migraine Preventive Medications (20200403) Yes Yes 46267 Finalised Not included in RMP Characterizing Otezla Use and Exposure Among Pregnant Women (20220012) Yes No 46292 Finalised Not included in RMP Persistence of AMGEVITA® in patients with plaque psoriasis: a retrospective database analysis from the British Association of Dermatology Biologics... Yes Yes 46337 Finalised Not included in RMP Characteristics and Risk Profile of Adult Patients Treated with Apremilast Included in the British Association of Dermatologists Biologic... No Yes 46340 Finalised Non-EU RMP-only Effectiveness of the Nplate Additional Risk Minimisation Materials Implemented in Australia (20210176) Yes Yes 46655 Ongoing Non-EU RMP-only Special Drug Use-Results Surveillance (all-case) for sotorasib in patients with KRAS G12C-mutated, unresectable, advanced and/or recurrent... No No 46882 Finalised Not included in RMP APPRECIATE™ (APREmilast ClinIcAl Treatment Experience in psoriasis): A Multi-center, Retrospective Observational Study of Real-World Experience of... No Yes 49061 Finalised Not included in RMP Effectiveness, Efficacy, and Safety of XGEVA (denosumab) in Chinese Patients With Giant Cell Tumor of Bone (GCTB): A Systematic Literature Review... Yes Yes 49101 Ongoing Not included in RMP Comparative Effectiveness of Osteoporosis Medications Among Female Medicare Fee-For-Service (FFS) Beneficiaries in the United States (20210088) No No 49104 Finalised Not included in RMP The Safety and Effectiveness of Denosumab Among Chinese With Osteoporosis and Glucocorticoid Exposure – a Real World Study in Taiwan (20220054) No Yes 49271 Planned Not included in RMP Real-world Evidence of the Use of a Carfilzomib Triplet Including an Anti-CD38 Antibody in Patients With Multiple Myeloma who Have Received at Least... No No 49757 Ongoing EU RMP category 3 Use of Erythropoiesis Stimulating Agents (ESAs) in Patients Receiving Myelosuppressive Chemotherapy in Europe and the UK (20190404) Yes No 103648 Ongoing Not included in RMP Retrospective Analysis of Second Primary Malignancies (SPM) Data From ASPIRE and ENDEAVOR Studies (20220146) Yes No 104114 Planned Not included in RMP A two-stage, prospective observational study describing the use and effectiveness of XGEVA®/ANJIAWEI® for the prevention of skeletal related events in... No No 104308 Ongoing EU RMP category 3 EVENITY® Risk Minimisation Materials Effectiveness Measurement in Australia (20220120) No No 104428 Planned Non-EU RMP-only Post-marketing Surveillance Study for Sotorasib in South Korea (20200009) No No 107685 Ongoing EU RMP category 3 An Observational Study to Describe Women Exposed to Apremilast During Pregnancy and Infant Outcomes During the First Year of Life (20210218) No No 107858 Planned Not included in RMP An observational study describing the effectiveness and safety of BLINCYTO® in Chinese adults with Philadelphia chromosome-positive relapsed or... No No